Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)

Market Cap	10.08B
Revenue (ttm)	1.33B
Net Income (ttm)	241.37M
Shares Out	174.35M
EPS (ttm)	1.37
PE Ratio	42.15
Forward PE	38.28
Dividend	0.43 (0.74%)
Ex-Dividend Date	Jun 11, 2025

Volume	900,888
Average Volume	1,659,346
Open	58.70
Previous Close	58.44
Day's Range	57.00 - 59.05
52-Week Range	29.89 - 73.66
Beta	0.27
RSI	44.63
Earnings Date	Apr 22, 2026

About SHA:688513

Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; Apualutamide, Bosutinib, Dacomitinib, Ibrutinib, Nilotinib HCL, Nintedanib, Relugolix, and Ruxolitinib Phosphate for oncological applications; Bricarace...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 1,522
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688513

Financial Performance

In 2024, SHA:688513's revenue was 1.35 billion, an increase of 20.82% compared to the previous year's 1.12 billion. Earnings were 238.23 million, an increase of 5.15%.